- Home
- TIL vs ENGN Comparison
TIL vs ENGN Comparison
Compare TIL & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIL
- ENGN
- Stock Information
- Founded
- TIL 2018
- ENGN 1999
- Country
- TIL United States
- ENGN Canada
- Employees
- TIL N/A
- ENGN N/A
- Industry
- TIL Biotechnology: Pharmaceutical Preparations
- ENGN
- Sector
- TIL Health Care
- ENGN
- Exchange
- TIL Nasdaq
- ENGN Nasdaq
- Market Cap
- TIL 230.1M
- ENGN 204.3M
- IPO Year
- TIL 2021
- ENGN N/A
- Fundamental
- Price
- TIL $27.56
- ENGN $3.15
- Analyst Decision
- TIL Buy
- ENGN Buy
- Analyst Count
- TIL 5
- ENGN 7
- Target Price
- TIL $119.00
- ENGN $23.29
- AVG Volume (30 Days)
- TIL 503.4K
- ENGN 74.0K
- Earning Date
- TIL 08-12-2025
- ENGN 06-12-2025
- Dividend Yield
- TIL N/A
- ENGN N/A
- EPS Growth
- TIL N/A
- ENGN N/A
- EPS
- TIL N/A
- ENGN N/A
- Revenue
- TIL N/A
- ENGN N/A
- Revenue This Year
- TIL N/A
- ENGN N/A
- Revenue Next Year
- TIL N/A
- ENGN N/A
- P/E Ratio
- TIL N/A
- ENGN N/A
- Revenue Growth
- TIL N/A
- ENGN N/A
- 52 Week Low
- TIL $9.62
- ENGN $2.65
- 52 Week High
- TIL $92.00
- ENGN $11.00
- Technical
- Relative Strength Index (RSI)
- TIL 51.84
- ENGN 37.77
- Support Level
- TIL $27.01
- ENGN $3.17
- Resistance Level
- TIL $42.79
- ENGN $3.44
- Average True Range (ATR)
- TIL 5.01
- ENGN 0.43
- MACD
- TIL -1.00
- ENGN -0.04
- Stochastic Oscillator
- TIL 9.82
- ENGN 16.67
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.